Merck, Inc.
🇵🇭Philippines
Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)
Phase 1
Completed
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00828269
A Study of the Effects of Single Dose Corticosteroids on Response to Allergens
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT00828061
Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 164
- Registration Number
- NCT00826176
Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)
Phase 3
Completed
- Conditions
- Anesthesia, GeneralNeuromuscular Blockade
- Interventions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 308
- Registration Number
- NCT00825812
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: PlaceboDrug: MK-0941Drug: Insulin
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 68
- Registration Number
- NCT00824616
Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00822757
Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)
Phase 3
Completed
- Conditions
- Varicella
- Interventions
- Biological: Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)Biological: Measles, Mumps, and Rubella Virus Vaccine Live (MMR)
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 598
- Registration Number
- NCT00822237
A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
Phase 1
Completed
- Conditions
- Postmenopausal Symptoms
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 29
- Registration Number
- NCT00820664
A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00818675
A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Phase 1
Completed
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 98
- Registration Number
- NCT00819039
- Locations
- 🇲🇽
MSD, Mexico City, Mexico
🇹🇷Merck Sharp & Dohme Ilaclari Ltd. Sti, Istanbul, Turkey
🇪🇸Merck Sharp and Dohme de Espana S.A., Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath